Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding

• References

• 1 Bowry ADK. et al. Meta-Analysis of the Efficacy and Safety of Clopidogrel Plus Aspirin as Compared to Antiplatelet Monotherapy for the Prevention of Vascular Events. Am J Cardiol 2008; 101: 960-966.
• 2 Scott SA. et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011; 90: 328-332.
• 3 Lu CY. et al. The importance of high-quality evidence of the long-term impact of nonfatal events used in randomized controlled trials: A case study of prasugrel. Clin Pharmacol Ther 2011; 90: 27-29.
• 4 Sorich MJ. et al. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost 2010; 08: 1678-1684.
• 5 Polasek TM. et al. Metabolic activation of clopidogrel:in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1. Therapeutic Advances in Drug Safety 2011; 02: 253-261.
• 6 Review Manager (RevMan). Version 5.1. 5.1 ed. The Nordic Cochrane Centre. The Cochrane Collaboration, Copenhagen. 2011
• 7 Bhatt DL. et al. Charisma Genomics Substudy: Evaluation of the CYP2C19 Polymorphism in a Prospective, Randomized, Placebo-Controlled Trial of Chronic Clopidogrel Use for Primary and Secondary Prevention. Available at: http://www.clinicaltrialresults.org/Slides/CHARISMA%20Genomics.ppt Accessed January 24, 2012
• 8 Wallentin L. et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial. Lancet 2010; 376: 1320-1328.
• 9 Mega JL. et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
• 10 Pare G. et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010; 363: 1704-1714.
• 11 Campo G. et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention: Relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011; 57: 2474-2483.
• 12 Sibbing D. et al. Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement. Circulation 2010; 121: 512-518.
• 13 Luo Y. et al. Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel. J Int Med Res 2011; 39: 2012-2019.
• 14 Harmsze AM. et al. The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics 2012; 22: 169-175.
• 15 Zabalza M. et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 2012; 98: 100-108.